Predictive Oncology Inc

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes clinical testing and contract research services that include the application of AI. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within corporate. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Predictive Oncology Inc advances in cancer research and cost optimization

POAI's Q2 2024 performance reflects progress in research, technology, and cost optimization strategies.
While facing challenges in financial metrics, the company's focus on innovation and shareholder value creation positions it for long-term success.
Opportunities lie in leveraging AI capabilities, strategic partnerships, and revenue growth initiatives to drive future growth and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

Predictive Oncology is leveraging AI to streamline drug discovery and development, improve outcomes in clinical testing and forge a new frontier of cancer research Predictive Oncology is leveraging AI to streamline drug discovery and development, improve outcomes in clinical testing and forge a new frontier of cancer research

Predictive Oncology Launches Website Highlighting AI-Powered Cancer Research Advancements

BEST Inc - ADR

Farmmi

Three penny stocks that you should know about in October 2021 The post Are Penny Stocks Worth Buying? Check These 3 Out Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are Penny Stocks Worth Buying? Check These 3 Out Right Now

ENGlobal

Seanergy Maritime Hlds

Making a list of penny stocks to buy next month? Check these three out The post Hot Penny Stocks to Watch In the Last Week of September appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch In the Last Week of September

Castor Maritime Inc

Endo International

Why investors are watching these penny stocks right now The post Do These Penny Stocks Deserve a Place On Your Watchlist? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Do These Penny Stocks Deserve a Place On Your Watchlist?

MINNEAPOLIS, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that on August 17, 2021, the stockholders approved an amendment to the Company's certificate of incorporation to increase the number of authorized shares of Company common stock from 100,000,000 to 200,000,000, and the amendment became effective on August 17, 2021. The approval was granted at the special meeting of stockholders convened on August 10, 2021 and adjourned to August 17, 2021.

Predictive Oncology Announces Results of Charter Amendment Proposal at Special Meeting

MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2021, and provided an update on business activities.

Predictive Oncology Reports Financial Results for Quarter Ended June 30, 2021, and Provides Business Update

Initial results demonstrate that AI models of genomic data can predict cancer outcomes. This has the potential to help personalize ovarian cancer treatments and drive the discovery of new therapies. Initial results demonstrate that AI models of genomic data can predict cancer outcomes. This has the potential to help personalize ovarian cancer treatments and drive the discovery of new therapies.

Predictive Oncology subsidiary, Helomics uses data from the 100,000 Genomes Project to better predict ovarian cancer outcomes

The stock price of Predictive Oncology Inc (NASDAQ: POAI) increased by 25.96% yesterday. This is why it happened.

POAI Stock Price Increased 25.96%: Why It Happened

Dare Bioscience

Second Sight Medical Products

GT Biopharma Inc

Current & former penny stocks to watch if you like biotech right now. The post Best Penny Stocks For Your July 2021 List?

Best Penny Stocks For Your July 2021 List? 8 Biotechs To Watch Now

Avinger

Borr Drilling Ltd

Borqs Technologies

Inpixon

Inuvo

Which penny stocks are investors watching with inflation on the rise? Here's 7 for your list The post Hot Penny Stocks to Buy to Avoid Inflation?

Hot Penny Stocks to Buy to Avoid Inflation? 7 For Your July Watchlist

MINNEAPOLIS, June 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), an AI-driven oncology and drug discovery company, announced today that two of their wholly owned subsidiaries, Soluble Biotech Inc. and TumorGenesis Inc. are both expanding their unique services by completing the fabrication and qualification of GMP facilities.

Predictive Oncology Inc.'s Subsidiaries Soluble Biotech Inc. and TumorGenesis Inc. are both constructing new GMP labs

Gran Tierra Energy

GEE Group

Limelight Networks

Meten Holding Group Ltd.

Qudian

Zomedica

Making a penny stocks watchlist for July? Check these 7 out The post Hot Penny Stocks to Buy Right Now?

Hot Penny Stocks to Buy Right Now? 7 For Your Watchlist

MINNEAPOLIS, June 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the closing of its previously announced registered direct offering of 15,520,911 shares of its common stock and warrants to purchase up to an aggregate of 15,520,911 shares of its common stock at a purchase price of $1.375 per share of common stock and related warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.25 per share, will become exercisable upon the Company increasing its authorized capital stock to 200 million shares, and will expire three (3) years following the date the warrants first become exercisable.

Predictive Oncology Announces Closing of $21.34 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Adamis Pharmaceuticals

Electrameccanica

Are these Robinhood penny stocks the best to watch in 2021? The post Best Penny Stocks to Buy on Robinhood?

Best Penny Stocks to Buy on Robinhood? 3 For Your Morning Watchlist

Aprea Therapeutics

Iterum Therapeutics Plc

Looking for well-funded biotech penny stocks? Check these 3 small-caps out The post Best Biotech Penny Stocks to Buy?

Best Biotech Penny Stocks to Buy? Here's 3 That Are Well Funded

MINNEAPOLIS, June 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale of an aggregate of 15,520,911 shares of its common stock and warrants to purchase up to an aggregate of 15,520,911 shares of its common stock at a purchase price of $1.375 per share of common stock and related warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.25 per share, will become exercisable upon the Company increasing its authorized capital stock to 200 million shares, and will expire three (3) years following the date the warrants first become exercisable. The closing of the offering is expected to occur on or about June 15, 2021, subject to the satisfaction of customary closing conditions.

Predictive Oncology Announces $21.34 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Innodata

LAIX Inc - ADR

Remark Hlds

These four penny stocks could get a huge boost from the success of the underlying companies' AI systems going forward. The post 4 Penny Stocks With the Potential to Become Top-Notch AI Players appeared first on InvestorPlace.

4 Penny Stocks With the Potential to Become Top-Notch AI Players

MINNEAPOLIS, June 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its three wholly owned subsidiaries, Helomics, TumorGenesis and Soluble Biotech, will be attending BIO DIGITAL, a key international biotech partnering event held virtually on June 10-11 & 14-18, 2021.

Predictive Oncology Inc. to Attend BIO DIGITAL, the World's Largest Biotech Partnering Experience

MINNEAPOLIS, May 20, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), an artificial intelligence driven oncology and drug discovery company, announced today that its wholly owned subsidiary, TumorGenesis (TumorGenesis.net), has partnered a deal with the Swedish firm Cellevate AB (Cellevate.com). The companies are combining TumorGenesis' medias with Cellevate's high engineered matrix materials. This partnering opens new territories for both companies.

Predictive Oncology Inc.'s Wholly Owned Subsidiary, TumorGenesis, Partners with Cellevate AB

MINNEAPOLIS, May 12, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended March 31, 2021 and provided an update on business activities.

Predictive Oncology Reports Financial Results for Quarter Ended March 31, 2021 and Provides Business Update

MINNEAPOLIS, April 27, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce today their newest Board Member Dr. Christina Jenkins.

Predictive Oncology Inc. Announces Newest Board Member

MINNEAPOLIS, March 23, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is excited to announce today that they have appointed J. Melville (“Mel”) Engle as Chief Executive Officer of the company.

Predictive Oncology Inc. Announces New CEO

MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) – Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the year ended December 31, 2020 and provided an update on business activities.

Predictive Oncology Reports Year End 2020 Financial Results, Provides Business Update

There is growing demand for AI use in drug development. Drug development deals go from $5 million to over $1 billion.

Predictive Oncology: Potentially Undervalued Drug Discovery AI Company

Helomics Researchers Complete Key Sequencing Milestones and Focus on AI-Driven Model Building Helomics Researchers Complete Key Sequencing Milestones and Focus on AI-Driven Model Building

POAI ‘s Helomics Division Announces Progress on Milestones for its AI-Driven Model of Ovarian Cancer

News for Predictive Oncology Inc Stock (POAI)